about
Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort.Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV.Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatmentProgression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.[Prevalence of serum antibodies against Bartonella ssp. in a health population from the south area of the Seville province]Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients.Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis.Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals.Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease.HAART and the liver: friend or foe?Incidence and natural history of hepatitis E virus coinfection among HIV-infected patients.HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma.Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection.Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack.Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.[Digoxin toxicity secondary to inhibition of digoxin intestinal metabolism in a patient receiving clarithromycin].Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals.Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients.Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis.Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients.Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection.
P50
Q31114657-4CC9874B-5AB5-4B6B-B26A-93D1A01F45C7Q34852032-36D7BF04-0D3A-4E13-9184-87AE28DA7D65Q35036061-BF1F0562-3A91-48E8-BDDC-7329A16D492EQ35862847-B19BD06D-B6EE-46B0-A6D6-E92FC74CCCA1Q36223683-3BBA3484-3B07-489C-81BA-24429D865CF0Q37863263-217994B2-F9D7-43D6-ABE7-A93BDA6755A4Q38236179-7C09F8EB-DA63-4ACD-A85B-5FFCA6C6D91BQ39877513-3394D60C-D4A8-4542-B569-9E4BF06CFC8BQ40043067-2872AE3E-DE7D-4AD0-8CF5-AA228EF10DB7Q40092302-AA02104E-E9C0-4A47-A792-E43495F6C246Q40360505-29846A80-FE35-424F-90A7-AD0B38FB97AEQ40437474-2B6084E4-06D3-422A-B69C-E22A4AFB443AQ40439142-88C8568A-EA2D-47A7-878D-7ED20D3DA9D4Q40501415-8F21AF85-1F73-4423-A59A-ED5C4EFF2940Q41008656-54FCC58C-748B-4AD5-B0E4-6E8E3363BF12Q41089110-0D4BE66D-5683-4379-93A5-84BFD3D9029AQ41117767-34DA75D0-88C6-4CB7-911B-624D0B781ECAQ41578791-D76B95B9-2E84-4F64-900E-1BACBF6085C7Q41586032-293C820C-A9E3-400E-B6BE-564CB53884E3Q41991102-BA311B43-0C0F-403B-8083-1475DDDCAEDAQ42208183-0A198916-997A-42CE-AC40-6ACC33B3D340Q42267887-CE314295-E21C-4832-99B7-E44E35A63D9CQ42937135-0E965A77-D150-4069-96BD-69E11F2A3E18Q42959234-A6E5B83B-E293-4ED5-8E1E-17CC0616CF8AQ42977116-B5764139-6677-41DB-9AB4-7B52A2126FCBQ42981865-383C810A-F868-42FB-ACB7-A65B625169D0Q42985479-0BEFDEB7-7D35-4BDE-BCBB-295DEEC2F6CBQ42989479-92FEC7E4-9F1E-4F41-9EE3-FAF46AA78C58Q43037839-32448DF6-C2A6-4CF2-A4C3-32037C1E462BQ43041036-5DD108AE-E381-4CEB-AAE0-A601EA19CD74Q43046515-127ED94C-C801-4221-AC08-22585E217CF8Q44838431-5A274BAB-6FE3-4E26-A683-96CF1B73D364Q45152357-92196D2B-AF3D-474A-A8B9-DC48A25913A5Q45330612-471271C3-F6FE-4C5F-8AB2-2ABE8C3063E6Q45358296-D102A796-2E96-4D0C-898B-22C5021C2A41Q45359060-9E133B24-6EC6-4DE0-AAFD-EFA8CE0F0E68Q45368121-35AD4A8E-28FA-4B6F-9888-A40599E59B52Q45381381-287354EC-A7CF-4383-916F-84D2032EF0D7Q45415285-3CF62FB5-4195-4DA5-89ED-C487D948DB95Q45423509-898E6F59-DE70-455E-A692-AB86BA9DF8A1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicolás Merchante
@ast
Nicolás Merchante
@en
Nicolás Merchante
@es
Nicolás Merchante
@nl
Nicolás Merchante
@sl
type
label
Nicolás Merchante
@ast
Nicolás Merchante
@en
Nicolás Merchante
@es
Nicolás Merchante
@nl
Nicolás Merchante
@sl
prefLabel
Nicolás Merchante
@ast
Nicolás Merchante
@en
Nicolás Merchante
@es
Nicolás Merchante
@nl
Nicolás Merchante
@sl
P106
P21
P31
P496
0000-0003-1120-8942